What Darflox Treats: Main Uses and Benefits

Darflox is relevant for managing symptoms associated with bacterial infections across domains where additional symptomatic support is needed. This medication is commonly applied in clinical settings that involve acute or unstable symptom patterns. These conditions primarily include uncomplicated and complicated urinary tract infections (UTIs), chronic bacterial prostatitis, and acute exacerbation of chronic bronchitis. It is also considered relevant for managing certain gastroenteritis infections, like infectious diarrheas, and some skin and soft tissue infections.

The medicine plays a role in managing symptom clusters that may become intense or disruptive, such as painful urination (dysuria), increased cough, and pelvic discomfort during flare-ups. The medicine is generally applied across domains where additional symptomatic support is needed during episodes of heightened physiological stress.

“The medicine is generally applied across domains where additional symptomatic support is needed during episodes of heightened physiological stress.”

---

Quick Fact: Relief for Uro-Respiratory Discomfort

Symptom Axis	Therapeutic Use
Systemic Imbalance	Applied in addressing symptoms related to inflammatory or irritative states
Physical Discomfort	Relevant for easing painful urination and pelvic discomfort
Functional Strain	Assists with maintaining functional stability during respiratory or urinary symptom escalation

Regulatory References

1. FDA Verification Portal (Philippines) for Prulibact

Eligibility Scope

Category	Statement Based on Regulatory Documents
Populations for whom use is allowed (as stated in label)	Adults (18 years and older) who do not have any listed contraindications or restrictions.
Populations for whom use is contraindicated	Individuals under 18 years of age with uncompleted skeletal development; patients who are pregnant or lactating; and those with known hypersensitivity to Darflox, other quinolone-type antibacterial agents, or any of the product’s excipients.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute prohibition); Not Recommended; Special Caution (Conditional use).

---

Resulting Eligibility Structure

The medicine is contraindicated for any patient with a history of tendon diseases related to the administration of quinolones. Use requires special caution or is not recommended in several populations. This includes patients with renal or hepatic impairment, those with CNS disorders predisposing to convulsion, and individuals with a history of myasthenia gravis. Patients with pre-existing aortic aneurysm risk should only use the medicine after a careful benefit-risk assessment. The profile strictly adheres to official restrictions defining use in the adult population only.

Interactions with other medicines and products

This section describes the officially documented interaction patterns of Darflox (Prulifloxacin) as reported in government regulatory documents, detailing changes in drug exposure and risk enhancement.

---

Pharmacokinetic and Timing Constraints

Co-administration with preparations containing multivalent cations—such as Aluminum/Magnesium antacids, supplements containing Iron, and products with Calcium—reduces the absorption of Prulifloxacin. To mitigate this effect, these substances and the H2-receptor antagonist Cimetidine must be administered 2 hours before or at least 4 hours after Darflox. Co-administration with Probenecid is documented to decrease the urinary excretion of Prulifloxacin, potentially leading to increased systemic exposure. Prulifloxacin may also cause a slight decrease in the clearance of Theophylline. Separately, the ingestion of milk is officially noted to decrease the drug's overall exposure (AUC) and urinary recovery.

---

Pharmacodynamic and Population Risks

The official profile notes several instances of potential risk enhancement. Concomitant use with the NSAID Fenbufen is associated with an increased risk of convulsions. The effects of Oral Anticoagulants like Warfarin may be enhanced, requiring close awareness. Use with Hypoglycemic Agents can lead to officially reported disturbances in blood glucose. Furthermore, the risk of tendinitis and tendon rupture when co-administered with Corticosteroids is noted as being particularly heightened in older patients and those with existing renal impairment.

Activating the Mechanism: Prodrug and Selective Targeting

Darflox is administered as the inactive prodrug Prulifloxacin, which must first be converted into its active metabolite, Ulifloxacin, via hydrolysis in the body. This active form then initiates the mechanism by selectively targeting the core bacterial enzymes, DNA Gyrase and Topoisomerase IV, which are essential for maintaining the integrity and function of the bacterial cell's genetic material. This specific enzyme targeting confers selective toxicity for bacterial targets.

---

Causal Cascade: Irreversible DNA Disruption and Killing

The active molecule, Ulifloxacin, acts as an inhibitor that forms a stable complex with the target enzymes and the bacterial DNA, preventing the crucial step of DNA re-ligation. This molecular disruption causes the accumulation of lethal double-strand DNA breaks, irreversibly halting the bacterial processes of replication and transcription. This cascade results in a bactericidal effect, which results in the rapid, active death of susceptible bacterial populations.

---

️ Mechanistic Limitations: Target Site Protection

The drug's mechanism is physiologically constrained when bacteria develop mutations, such as in the gyrA and parC genes, which alter the enzyme binding sites and reduce Ulifloxacin's effectiveness. Alternatively, over-expressed efflux pumps can actively transport the drug out of the bacterial cell, preventing the attainment of the required intracellular concentration for effective enzyme inhibition.

How to Use Darflox: Official Administration Guidelines

Darflox (Prulifloxacin) is an antibiotic governed by specific usage protocols detailed in official prescribing information. Its administration is standardized and must adhere to the route, dose, and frequency established in official product labels.

---

Administration Scope

Instruction	Detail
Route of administration	Oral administration only, via ingestion of the film-coated tablet.
Dosing schedule	600 mg once daily is the standard dose for multi-day courses, including complicated urinary tract infections, chronic bacterial prostatitis, and acute exacerbation of chronic bronchitis. A single dose of 600 mg is used for acute uncomplicated lower UTIs.
Preparation requirements	Tablets must be swallowed whole with water and must not be crushed, split, or chewed.
Course duration	Duration ranges from a single dose up to 28 days, based on the specific infection being addressed.

---

Contextual Usage Principles

The usage protocol for Darflox includes specific rules concerning co-administration and patient populations. The medicine must be administered either 2 hours before or 4 hours after any intake of antacids containing magnesium or aluminum, or supplements containing iron or zinc, to ensure proper absorption. Dosage adjustments are required for certain patients: those with severe renal impairment (Creatinine Clearance <30 mL/min) typically require a reduction to 300 mg once daily. Furthermore, the medicine is not approved for use in the pediatric population (individuals under 18 years of age).

Research Evidence / Overview of Studies for Darflox (Prulifloxacin)

This overview summarizes the type of research that has been conducted on Darflox and how scientific findings are described in official sources, focusing only on the structure of the evidence and areas of uncertainty.

---

Evidence for Use in Urinary Tract Infections (UTIs)

Research conducted comparative studies, evaluating Darflox alongside established antibiotics, such as ciprofloxacin. These short-term, randomized controlled trials were applied in studies examining patient-reported experiences related to physical discomfort and outcomes linked to inflammatory or irritative states associated with UTIs. The populations observed in these trials included adults and often involved older individuals, as well as those with underlying conditions that make UTIs more complex. Studies described patterns where a percentage of patients reached measured microbiological and clinical success endpoints in trials comparing Darflox to standard antibiotic therapy. The research provides insight into short-term changes in the context of acute infection treatment.

Evidence for Use in Acute Exacerbation of Chronic Bronchitis (AECB)

Studies focusing on episodes where symptoms become more noticeable—such as an acute exacerbation of chronic bronchitis (AECB)—were conducted using randomized, comparator-controlled designs. Research was applied in studies examining patient-reported experiences for outcomes related to systemic or functional imbalance, such as breathing difficulty and changes in cough or sputum. Studies described patterns where a percentage of the observed populations reached the predetermined clinical outcome measured shortly after the study intervention period finished. Research also monitored outcomes reflecting daily functioning or activity level, with findings showing patterns related to symptom evolution during the study period.

Long-Term Studies and Follow-up Durability

The research exploring short-term symptom changes primarily involved follow-up durations that ended shortly after the completion of the study intervention period. While some studies for AECB included a follow-up of up to six months, long-term effects are not fully established for all indications. Due to the chronic nature of the condition, long-term follow-up of at least six months is considered essential for assessing recurrence, but not all trials reported data for this duration.

What Remains Uncertain About Darflox Research

A primary limitation noted in the research is that follow-up durations were limited across many of the core studies, especially for conditions where symptoms can have cycles of stability and flare-ups. This means that long-term outcomes are not fully established. Furthermore, evidence quality varies across studies, and comparative evidence is limited in specific populations. Findings describe group patterns, and research does not offer individual predictions on whether a patient will respond similarly, as study results reflect the specific conditions under which they were conducted.

Common questions about Darflox (FAQ)

---

Q: What is Darflox used for besides the main condition?

Regulatory documents specify that Darflox is approved for treating specific bacterial infections, including complicated urinary tract infections and chronic bacterial prostatitis. It is also indicated for the management of acute exacerbation of chronic bronchitis (AECB). Specific official labels may also list other uses, such as certain infections of the skin and soft tissues.

---

Q: How quickly does Darflox start to work?

Regulatory pharmacokinetic studies indicate that the active form of Darflox, known as ulifloxacin, reaches its maximum concentration in the bloodstream ( T max) in approximately one hour after the tablet is taken. This represents the point at which the concentration of the active substance in the body is at its highest.

---

Q: What happens if I miss a dose of Darflox?

Patient information leaflets from regulatory agencies provide general guidance on a missed dose. Official patient information generally indicates that patients may take the missed dose as soon as they remember. If the time for the next scheduled dose is near, the patient information suggests skipping the missed dose and continuing with the regular schedule.

---

Q: What should I do if the side effects of Darflox feel severe?

Official regulatory safety warnings advise that if a patient experiences signs of a serious adverse reaction—such as tendon pain, severe rash, breathing difficulty, or severe changes in blood glucose—prompt communication with a healthcare professional or seeking immediate medical attention is necessary. This guidance is essential when reacting to the most serious events documented in the product profile.

---

Q: Can Darflox be taken with common pain relievers?

Official product information indicates that taking Darflox alongside the non-steroidal anti-inflammatory drug (NSAID) Fenbufen is associated with an increased risk of convulsions. The regulatory label does not specifically address common non-NSAID pain relievers like acetaminophen (paracetamol). Official guidance emphasizes the importance of a patient's healthcare provider reviewing all their current medications.

---

Q: Are there any foods or drinks to avoid while taking Darflox?

Regulatory documents note that ingesting milk can decrease the overall amount of Darflox the body absorbs. Furthermore, the official regulatory documents indicate that the medicine should be separated from antacids and supplements containing metal ions like Iron or Zinc by 2 to 4 hours. This timing separation is needed to ensure the medicine is properly absorbed.

---

Q: Can Darflox be taken by people with diabetes?

Official product information notes that use requires special caution in people with diabetes or those taking hypoglycemic agents (medicines that lower blood sugar). This is because the drug can lead to disturbances in blood glucose levels, including severe lows (hypoglycemia). This area of risk is carefully considered by healthcare providers before prescribing.

---

Q: What does 'contraindication' mean for Darflox?

A contraindication is a term used in official regulatory documents to signify an absolute prohibition of using the medicine in specific patient situations. This prohibition is established because the potential risk in those situations is considered unacceptably high. This includes individuals with specific known hypersensitivities or certain conditions of the tendons linked to the quinolone class.

---

Q: Is Darflox safe to use if I have had a heart issue in the past?

Official safety information notes a risk associated with Prolongation of the QT interval, which refers to a change in the electrical activity of the heart. This change carries a risk of serious ventricular arrhythmias (irregular heart rhythms). This indicates that existing heart conditions are listed as a risk factor in the official prescribing profiles.

---

Q: Does Darflox lose its effectiveness over time?

Regulatory science indicates that the effectiveness of Darflox may be limited by the development of bacterial resistance. This occurs when the targeted bacteria develop genetic changes (mutations) or activate internal mechanisms, such as efflux pumps, that actively transport the drug out of the bacterial cell. This process prevents the drug from reaching the concentration needed to kill the bacteria.

---

Q: Does Darflox cause any long-term health issues?

Official safety documents describe potentially disabling and permanent serious adverse reactions, such as Peripheral Neuropathy and Tendinitis/Tendon Rupture. While these are known long-term risks, regulatory research overviews also note that the follow-up duration for some clinical studies was limited, meaning long-term effects beyond those documented are not fully established.

---

Q: How is Darflox eliminated from the body?

The active form of the medicine is removed from the body primarily through two routes: the renal route (via the kidneys) and the fecal route (via the bile). Regulatory documents show that the drug has an elimination half-life of approximately 10.6 to 12.1 hours. This is the time it takes for the amount of drug in the body to be reduced by half.

---

Q: Can taking Darflox affect my driving or operating machinery?

Official safety warnings caution that the medicine may cause side effects, such as dizziness or sleep disorders, which affect the central nervous system. Because of this potential, regulatory labels describe that the medicine may impair the ability to drive or operate heavy machinery.

---

Q: What if I accidentally took too much Darflox?

Regulatory labels describe that in the event of an overdose, prompt communication with a doctor or the nearest hospital/poison control center is necessary. Official information does not list any specific antidote for an overdose of this medicine.

---

Q: Are there any known interactions between Darflox and alcohol?

Some official product information describes the need for caution regarding the use of alcohol while taking Darflox. This caution is based on the potential for alcohol to worsen certain central nervous system side effects, such as dizziness, or to place additional burden on liver function.

---

Q: Is it OK to stop taking Darflox suddenly?

Regulatory guidelines state that the completion of the full course of treatment is necessary to ensure the complete elimination of the infection. Official documents state that the medicine is not intended to be stopped suddenly, even if symptoms appear to improve.

---

Q: Why do doctors check liver function before prescribing Darflox?

Official regulatory documents indicate that the use of Darflox requires special caution in patients who have hepatic impairment, which means reduced liver function. Since the drug's safety profile and how the body handles the medicine are closely tied to the liver, the presence of this caution signals that a healthcare provider may need to evaluate liver function before or during the course of therapy.

How to Store and Dispose of Darflox

Storage Requirements

Darflox must be stored at room temperature, specifically at or below mathbf30 C (86 F), to maintain its stability. The product requires protection from light and must remain in its original container/blister pack. It is mandatory that the medicine not be frozen.

Like all prescription medications, Darflox must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal must adhere to official pharmaceutical waste guidelines. Unused or expired Darflox must not be thrown into household trash or poured down a sink or toilet (wastewater). The correct disposal method is to return the medicine to a pharmacist or utilize a local drug take-back or collection service, following local environmental protection regulations.